1 Ochratoxin A status at birth is associated with reduced birthweight and ponderal index

2 in rural Burkina Faso

3 Authors:

- 4 Yuri Bastos-Moreira,^{1,2} Alemayehu Argaw,² Giulianmichela Di Palma,³ Trenton Dailey-
- 5 Chwalibóg,² Jasmin El-Hafi,^{1,4} Lionel Olivier Ouédraogo,^{2,5} Laeticia Celine Toe,^{2,6} Sarah De
- 6 Saeger, ^{1,7} Carl Lachat,² and Marthe De Boevre¹

7 Affiliations:

- 8 ¹Center of Excellence in Mycotoxicology and Public Health, MYTOX-SOUTH[®]
- 9 Coordination Unit, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium
- ² Department of Food Technology, Safety and Health, Faculty of Bioscience Engineering,
- 11 Ghent University, Ghent, Belgium
- ¹² ³Department of Chemistry, University of Torino, Torino, Italy
- ⁴ Institute of Food Chemistry, University of Münster, Münster, Germany
- ⁵Laboratoire de Biologie Clinique, Centre Muraz, Bobo-Dioulasso, Burkina Faso
- ⁶ Unité Nutrition et Maladies Métaboliques, Institut de Recherche en Sciences de la Santé
- 16 (IRSS), Bobo-Dioulasso, Burkina Faso
- ⁷ Department of Biotechnology and Food Technology, Faculty of Science, University of
- 18 Johannesburg, Doornfontein Campus, Gauteng, South Africa

19 **Corresponding author**

- 20 Marthe De Boevre; Ottergemsesteenweg 460, 9000 Ghent, Belgium;
- 21 Marthe.DeBoevre@UGent.be

22	Abbreviations: AFs, aflatoxins; AFB1, aflatoxin B1; AFG1, aflatoxin G1; AFM1, aflatoxin
23	M1; AIC, Akaike Information Criterion; BEP, balanced energy-protein; BIC, Bayesian
24	Information Criterion; BioSpé, Biospecimen; CIT, citrinin; DON, deoxynivalenol; FB1,
25	fumonisin B1; GA, gestational age; IARC, International Agency for Research on Cancer; IFA,
26	iron-folic acid; LAZ, length-for-age z-score; LBW, low birth weight; LMICs, low-and-middle
27	income countries; LOD, limit of detection; LLOQ, lower limit of quantification; MISAME,
28	MIcronutriments pour la SAnté de la Mère et de l'Enfant; MUAC, mid-upper arm
29	circumference; OTA, ochratoxin A; PTB, preterm birth; SGA, small-for-gestational age;
30	UPLC-MS/MS, ultra-performance liquid chromatography-tandem mass spectrometry; VAMS,
31	volumetric absorptive microsampling; WAZ, weight-for-age z score; WLZ, weight-for-length

32 z score; ZAN, zearalanone; ZEN, zearalenone.

33 Abstract

Background: Mycotoxin exposure during pregnancy has been associated with adverse birth
outcomes and poor infant growth. We assessed multiple biomarkers and metabolites of
exposure to mycotoxins at birth and their associations with birth outcomes and infant growth
in 274 newborns in rural Burkina Faso.

38 Methods and findings: Whole blood microsamples were analyzed for mycotoxin 39 concentrations in newborns in the Biospecimen sub-study nested in MISAME-III trial using 40 ultra performance liquid chromatography coupled to tandem mass spectrometry. Unadjusted 41 and adjusted associations between mycotoxin exposure, and birth outcomes and infant growth at 6 months were estimated using linear regression models for continuous outcomes and linear 42 43 probability models with robust variance estimation for binary outcomes. Infant growth 44 trajectories from birth to 6 months were compared by exposure status using mixed-effects 45 models with random intercept for the individual infant and random slope for the infant's age. 46 Ochratoxin A (OTA) exposure was detected in 38.3% of newborns, with other mycotoxins 47 being detected in the range of 0.36% and 4.01%. OTA exposure was significantly associated 48 with adverse birth outcomes, such as lower birthweight (β (95% CI): -0.11 kg (-0.21, 0.00); p = 0.042) and ponderal index (β (95% CI): -0.62 gm/cm³ (-1.19, -0.05); p = 0.034), and a 49 50 marginally significant lower height growth trajectories during the first 6 months (β (95% CI): -0.08 cm/mo (-0.15, 0.0); p = 0.057). 51

52 Conclusions: OTA exposure was prevalent among newborns and also associated with lower 53 growth at birth and during the first 6 months. The results emphasize the importance of 54 nutrition-sensitive strategies to mitigate dietary OTA, as well as adopting food safety 55 measures in Burkina Faso during the fetal period of development.

- 56 Keywords: birth outcomes, exposomics, growth, low- and middle-income countries,
- 57 MISAME-III, mycotoxins, sub-Saharan Africa, ochratoxin A

58 Background

59 Mycotoxins are toxic fungal secondary metabolites that contaminate a wide spectrum of 60 essential foods worldwide, including staple crops consumed by the most vulnerable populations 61 (1). Foodstuffs in West Africa are commonly affected by mycotoxins (2,3) since the climate, 62 where there is high temperature and humidity, is favorable for their production (4.5). Maternal nutrition affects both the pregnancy's process and the newborn's well-being (6). In low-and 63 64 middle-income countries (LMICs), adverse pregnancy outcomes are common including low 65 birth weight (LBW), preterm birth (PTB) and/or small-for-gestational age (SGA) (7). Several epidemiological studies have indicated that mycotoxin exposure is extensive in newborns (8-66 11). 67

68 The International Agency for Research on Cancer (IARC) categorizes aflatoxin B1 (AFB1) as 69 carcinogenic to humans (Group1), and fumonisin B1 (FB1) and ochratoxin A (OTA) as possible 70 human carcinogens (Group 2B) (12). The human fetus is vulnerable to health effects resulting 71 from in utero exposure to environmental chemicals (13). Formerly, higher AF exposure, in 72 utero and in early life, has been linked with stunting and/or underweight, while children with 73 high fumonisins exposure were also shorter and lighter (14). In addition, research has also 74 shown that OTA can cross the placental barrier in humans (15), and is reported to also have 75 other toxic effects in humans including immunotoxicity and nephrotoxicity (16-18).

A literature review by Arce-López *et al.* (2020) concluded that OTA is often detected in whole blood, plasma and serum samples (19). Authors reported frequency levels of 64.9% (20–23), and concluded that the global population is generally exposed to OTA due to its long half-life in these matrices (19). This exposure during the critical first 1,000 days of life (10) might contribute to adverse fetal and infant outcomes (24). Generally, birthweight is an indicator of

both maternal health and nutrition status, and also the infant's well-being. Infants born with LBW are at increased risk of several short- and long-term consequences, including neonatal mortality, childhood stunting and impaired immune function (25–27). Nevertheless, research investigating the association between mycotoxins exposure and birth and infant growth outcomes have reported inconsistent results (28–31).

In Burkina Faso, limited biological and toxicological food contamination data are available 86 87 (32), and legislation and regulations regarding mycotoxins are often not implemented (33,34). 88 Using data from the Biospecimen (BioSpé) sub-study of the MISAME-III (MIcronutriments 89 pour la SAnté de la Mère et de l'Enfant) trial in rural Burkina Faso, we previously reported a 90 prenatal exposure to multiple mycotoxins among pregnant women from a rural Burkinabé 91 setting, and found no evidence of associations with adverse birth outcomes and infant growth 92 (in publication (35)). In the present study, we aimed to quantify newborn mycotoxin exposure 93 at birth and investigated the association with birth outcomes and infant growth in the same 94 mother-newborn dyads.

95 Methods

96 Study setting, participants, and design

97 Study protocols for the main MISAME-III trial (36) and the BioSpé sub-study nested under 98 the MISAME-III trial (37) were published previously. The main MISAME-III study is a 2 x 2 99 factorial randomized controlled trial evaluating the effect of balanced energy-protein (BEP) 100 supplementation to mothers during pregnancy (prenatal intervention) and lactation (postnatal 101 intervention) on maternal and child outcomes. In a subsample from the main MISAME-III 102 trial (Figure 1), a BioSpé sub-study was conducted aiming to understand the physiologic 103 mechanisms through which the BEP supplement affects the maternal and child outcomes by

104 way of multi-omics analyses, human biomonitoring of contaminants (mycotoxins, black
105 carbon, gut enteropathogens and pesticides), and analysis of relative telomere length and
106 mitochondrial DNA content (37).

107 The study was conducted in 6 rural health center catchment areas in the district of Houndé in 108 the Hauts-Bassins region of Burkina Faso. The study area is characterized by a Sudano-109 Sahelian climate with a dry season running between September/October and April, and 110 agricultural activities being the main livelihood of the community. Results from a previously 111 conducted dietary survey in a sub-sample of the MISAME-III pregnant women showed the 112 habitual diet during pregnancy is nondiverse, predominantly based on maize with a 113 complement of leafy vegetables (38). Grains, roots, tubers and plantains together contributed 114 68% of the total calorie intake during pregnancy. Almost all participants (95%) consumed the 115 main staple dish tô, which contributed 42% of the total energy intake. Tô is a stiff maize 116 dough often served with a watery sauce containing green-leafy vegetables (okra, hibiscus, and 117 baobab leaves) or other vegetables such as eggplant, with or without meat, fish, or 118 caterpillars. Other food groups such as fruits, dairy, eggs, fish, and meat contributed very 119 small amounts to the total energy intake (39).

120 **Exposure and outcomes**

121 The present study considered exposure to a range of mycotoxins listed in Table 2. However, 122 aflatoxin B1 (AFB1)-lysine exposure was not assessed due to the current unavailability of the 123 commercial analytical standard for this specific mycotoxin. Mycotoxin exposure was defined 124 as the detection of a concentration \geq the limit of detection (LOD) in whole blood 125 microsamples.

126	The outcomes of interest were birth outcomes, such as birth weight, SGA, LBW, gestational
127	age (GA), PTB, length, mid-upper arm circumference (MUAC), head circumference, ponderal
128	index, chest circumference, and infant growth and nutritional status at the age of 6 months,
129	such as length-for-age z-score (LAZ), weight-for-age z-score (WAZ), weight-for-length z-
130	score (WLZ), MUAC, head circumference, hemoglobin, stunting, underweight, wasting and
131	anemia. We additionally assessed the associations between mycotoxin exposure and infant
132	growth trajectories (height, weight, upper-arm and head circumferences) during the first 6
133	months postpartum.
134	PTB was defined as the birth of a newborn before 37 completed weeks of gestation. SGA was
135	defined as a newborn weight less than the 10 th percentile of weight for the same GA and sex

according to the International Fetal and Newborn Growth Consortium for the 21st Century

137 (INTERGROWTH-21st) (40). Anthropometric *z*-scores of LAZ, WAZ and WLZ were

138 calculated based on the WHO Child Growth Standards with stunting, underweight and

139 wasting defined as LAZ, WAZ and WLZ values below 2 SD from the median value for same

140 age and sex from the reference population (41). Newborn Rohrer's ponderal index was

141 calculated as weight in g divided for length in cm cubed (i.e., weight/length³ (g/cm³) \times 1,000).

142 Data collection

The MISAME-III trial data were collected through computer-assisted personal interviewing using SurveySolutions (version 21.5) on tablets and then transferred to a central server at Ghent University. Sociodemographic and other relevant characteristics of participants and study households were collected at baseline during the first and early second trimester of pregnancy. All newborn anthropometry measurements were taken within 12 hours of birth, whereas mothers were invited for follow-up growth assessment every month until 6 months of

age. Measurements were taken in duplicates and a third measurement was taken in case of a large discrepancy between the duplicate measurements. Length was measured to the nearest 1 mm with a Seca 416 Infantometer, weight was measured to the nearest 10 g with a Seca 384 scale, and head circumference, thoracic circumference and MUAC were measured to the nearest 1 mm with a Seca 212 measuring tape. GA was determined using a portable ultrasound (SonoSite M-Turbo, FUJIFILM SonoSite, Bothell, Washington, USA) during the first and early second trimester of pregnancy.

156 Blood sample collection and laboratory analysis

157 Samples collection and lab analysis procedures were described in detail previously (37).

158 Newborn samples were collected between May and October 2021 within 12 hours of birth in

all newborns. An amount of 40 of capillary whole blood was collected by capillary sampling

160 onto VAMS tips ($2 \times 20 \,\mu\text{L}$ VAMS tips), namely MitraTM, via direct heel incision for

161 mycotoxins analysis (37). Then, VAMS tips were stored in 20 µL Mitra Clamshells and

162 transported from the health centers to the Institut de Recherche en Sciences de la Santé in

163 Bobo-Dioulasso, Burkina Faso for shipment at room temperature to the Centre of Excellence

164 in Mycotoxicology and Public Health, Faculty of Pharmaceutical Sciences, Ghent University,

165 Belgium. For storage at -80°C until analysis, VAMS were placed in Mitra Autoracks (96-

166 Sampler, item number: 108) inside a storage bag containing desiccant bags (item number:

167 AC-SS02). Items used for VAMS collection were purchased from Neoteryx (Torrance,

168 California, USA).

169 A VAMS multi-mycotoxin extraction (42) began by transferring the VAMS tips from the

170 plastic handles into 2 mL Eppendorf tubes, and pipetting 250 µL extraction solvent

171 (acetonitrile/water/acetic acid, 59/40/1, v/v/v), containing the internal standards ¹³C₁₇–AFB1

172	$(0.125 \ \mu g/L)$ and ${}^{13}C_{15}$ – deoxynivalenol (DON) (0.25 $\mu g/L$), ${}^{13}C_{34}$ –FB1 (0.25 $\mu g/L$) and
173	$^{13}\text{C}_{18}\text{-}\text{zearalenone}$ (ZEN) (0.125 $\mu\text{g/L}$), to the sample tubes. Subsequently, samples were
174	ultrasonicated for 30 minutes and shaken for 60 minutes at 25°C with rotation at 1,400 rpm in
175	a Biosan TS-100 Thermo-Shaker followed by centrifugation (10 minutes at 10,000g, room
176	temperature). The tips were discarded, and the supernatant was pipetted to an 8 mL glass tube
177	and evaporated under nitrogen on a Turbovap LV Evaporator (Biotage, Charlotte, USA).
178	Afterwards, the extracts were reconstituted in 50 μ L of injection solvent (methanol/water,
179	60/40, v/v), vortexed, centrifuged (for 10 min at 5000 g) and filtered (22 μ m, PVDF,
180	Durapore [®] ,Cork, Ireland). Lastly, samples were transferred into vials before 10 μ L were
181	injected into an Acquity ultrahigh performance liquid chromatography (UPLC) system
182	(Waters®, Manchester, UK) equipped with an Acquity HSS T3 100×2.1 mm UPLC column
183	(1.8 μm particle size) and Acquity Vanguard HSS T3 10 \times 2.1 mm UPLC pre-column (1.8 μm
184	particle size), both from Waters® (Manchester, UK). Detailed instrument parameters can be
185	found in a previous study (42).

186 Statistical analysis

187 Data management and statistical analyses were performed using Stata (Stata Statistical

188 Software: release 17.0; StataCorp), and a 2-sided statistical significance was considered at *p*

189 <0.05. Descriptive statistics are presented using means \pm SD or medians (range) for the

190 continuous variables, depending on the nature of the data distribution, and frequencies

191 (percentages) for nominal variables.

In the study sample, only exposure to OTA was found in an adequate number of newborns to assess the association with birth outcomes and infant growth. The association between OTA exposure and the study outcomes at birth and 6 months of age was evaluated using linear

regression models for the continuous outcomes and linear probability models with robust
variance estimation for the binary outcomes. All models were adjusted for clustering by the
health center catchment areas and allocation for the prenatal and postnatal BEP interventions.
Furthermore, adjusted models additionally included the covariates maternal age, primiparity,
baseline BMI and hemoglobin concentration, household size, wealth index score, access to
improved water and sanitation, and food security status.

201 We also compared OTA exposed and non-exposed groups by growth trajectories from birth to 202 6 months. For this purpose, we fitted mixed-effects regression models with random intercept 203 for the individual infant and random slope for the infant's age (months). We explored the best 204 growth trajectory fitting the data by visual inspection of graphs and comparing model fit 205 indices including AIC (Akaike Information Criterion) and BIC (Bayesian Information 206 Criterion) values. Accordingly, we applied quadratic models (for the outcomes height, weight 207 and MUAC) and restricted cubic spline model with 4 knots (for the outcome head 208 circumference). We considered an unstructured covariance matrix for the correlation among 209 repeated measurements within an individual. Fixed effects in the model included the main 210 effect of OTA exposure, the main effect of age, and exposure by age interaction, which the 211 later estimates the difference in monthly changes in the outcome between exposure and 212 unexposed groups. Models were further adjusted for the aforementioned covariates.

In a further exploratory analysis, we evaluated potential interactions between OTA exposure and the allocation to the maternal BEP interventions on the study outcomes. For this purpose, interaction terms between OTA exposure and the prenatal and postnatal BEP interventions were specified in the models with the presence of interaction was considered at p < 0.10. Lastly, Cohen's weighted kappa test was used to assess the level of agreement between mother-newborn OTA exposure status. Results were reported as percentage agreement and

11

- 219 Cohen's weighted kappa values. The following cut-offs were used: Kappa values ≤ 0 no
- 220 agreement, 0.01–0.20 none to slight, 0.21–0.40 fair, 0.41–0.60 moderate, 0.61–0.80
- substantial, and 0.81–1.00 almost perfect agreement (43).

222 **Results**

- 223 Mother-newborn dyads characteristics
- Birth outcomes and infant growth at 6 months were assessed on 274 and 255 newborns,
- respectively (Figure 1). Mean \pm SD age of the mothers was 24.3 \pm 5.63 years and 45.3% of
- mothers had at least a primary education (**Table 1**). The mean \pm SD maternal BMI at study
- inclusion was 22.1 \pm 3.22 kg/m² with 6.93% underweight (BMI<18.5 kg/m²). More than two-
- thirds (70.3%) of the newborns were from food insecure households and 29.9% of their
- 229 mothers were anemic at study enrollment during the first/early second trimester of pregnancy.
- 230 Mycotoxins exposure and newborn and infant growth and nutritional status
- 231 The laboratory analysis indicated that, aside from OTA, almost all newborns were found to be
- not exposed to most mycotoxins (**Table 2**). OTA exposure was detected in 38.3% of the
- 233 newborns with a median (range) concentration of <LOD (<LOD, 3.61) µg/L. The LOD for

234 OTA as 0.09 µg/L. The UPLC-MS/MS chromatograms of OTA are shown in Figure 3.

235 Other mycotoxins such as AFB1, aflatoxin G1 (AFG1), aflatoxin M1 (AFM1), DON, citrinin

(CIT), zearalanone (ZAN) and ZEN were detected in the range of 0.36% and 4.01% of

newborns. For the remaining 26 mycotoxins analyzed, no exposure was detected throughwhole blood analysis.

In the unadjusted models, newborn OTA exposure was found to be negatively associated (p < p

240 0.05) with birth outcomes, such as birthweight, MUAC, ponderal index and chest

circumference, as well as with LAZ at the age of 6 months (**Table 3 & 4**). These associations remained significant after adjustment for relevant covariates only for birth weight (adjusted β (95% CI): -0.11 kg (-0.21, 0.00); p = 0.042) and ponderal index (adjusted β (95% CI): -0.62 gm/cm3 (-1.19, -0.05); p = 0.034). Likewise, newborns who were exposed to OTA had marginally significantly lower height growth trajectories than their counterparts without OTA

246 exposure (adjusted β (95% CI): -0.08 (-0.15, 0.00) cm/month; p = 0.057) (Figure 2).

247 There was also a significant interaction between newborn OTA exposure status and the 248 maternal prenatal BEP intervention on the outcome child anemia status at 6 months of age 249 $(p_{\text{interaction}} = 0.074)$ (Supplemental Table 1). OTA exposure was significantly associated with 250 higher anemia prevalence among newborns of mothers who did not receive prenatal BEP 251 supplementation (adjusted β (95% CI): 18.7% (2.00, 35.3); p = 0.029), while no significant 252 association was detected among newborns whose mothers received the prenatal BEP 253 supplementation (adjusted β (95% CI): 0.08% (-19.1, 19.3); p = 0.993). In the present study, 254 there was a 63.0% agreement between mother-newborn OTA exposure status and the kappa 255 value was classified as fair (Kappa = 0.27).

256 Discussion

257 There is a growing concern about the potential adverse health and developmental

258 consequences of fetal mycotoxins exposure. The present study found a high prevalence of

259 OTA exposure (38.32%) amongst newborns at birth. Exposures to mycotoxins, such as

AFG1, AFB1, AFM1, CIT, DON, ZAN and ZEN were detected in relatively fewer subjects,

- 261 whereas other mycotoxins were not detected. Moreover, we found that OTA exposed
- 262 newborns had significantly lower birthweight and ponderal index than their non-exposed
- 263 counterparts. OTA exposed newborns also had marginally significantly lower height growth

trajectories. Finally, an exploratory analysis indicated that maternal prenatal BEP
supplementation may offset the effect of OTA exposure on increased anemia prevalence at 6
months of age.

267 This is the first study to report the level of mycotoxins exposure in newborns using whole 268 blood microsamples. OTA is produced predominantly by some Aspergillus, Monascus, and 269 Penicillium species, which frequently contaminates cereals and derived products, dried fruit, 270 coffee, cocoa, spices, wine and cured pork products. Considering that in Burkina Faso maize 271 is the second most cereal produced, the Burkinabé population is often exposed to OTA (44-272 46). A study in Sierra Leone reported OTA exposure in 25% of cord blood samples in 273 newborns (range: $0.2-3.5 \mu g/L$). However, the study detected a high prevalence of overall 274 exposure to AFB1, AFM1, aflatoxicol, AFB2, AFM2, AFG1 and AFG2 (90.6%), while the 275 present study showed limited exposure to AF except AFB1-lys which was not analyzed (11). 276 The occurrence of OTA detected in the present study is also comparable to previous literature 277 using adult samples. Fan et al. (2019) analyzed plasma samples of 260 adults in China and 278 detected OTA in 27.7% of samples (range: 0.31-9.18 µg/L) (21), likewise in another study the 279 OTA prevalence was 28% in serum samples from Tunisia (range: 0.12 and 11.67 µg/L) (22). 280 On the other hand, exposure to mycotoxins other than OTA was found to be low in our study 281 population as compared to what has been reported previously in LMICs (8,23,48,49). The 282 variations in physicochemical properties of mycotoxins can lead to differences in their 283 toxicokinetic profiles, which results in different excretion amounts and times. Therefore, it is 284 conceivable that the used UPLC-MS/MS system may not detect the lowest concentrations of 285 mycotoxin metabolites. Further research is required on mycotoxins' stability during the 286 processing of foodstuffs, their fate in the digestive system as well as toxicodynamic and 287 toxicokinetic studies (50). Additionally, the knowledge of the formation process of these

14

metabolites and the understanding of their structure and molecular mass can solve the
analytical and technological challenges associated with these metabolites. Therefore, given
these facts, there may be underreporting of exposure to certain mycotoxins due to their shorthalf lives.

292 The teratogenic effects of OTA have been well reported in animal studies. Reduced birth 293 weight and craniofacial abnormalities are the most frequent reported outcomes (51). Oral 294 administration of OTA at 5 mg/kg body weight to pregnant rats was reported to cause a 295 reduced weight of the fetus as well as frequent hemorrhages (52–54). In addition, a single oral 296 dose of OTA at 4 mg/kg body weight caused abortions, maternal deaths and reduction in 297 maternal and fetal body weights (51). In the present study, results indicated a reduction of 298 0.11 kg in birthweight in newborns exposed to OTA compared to unexposed newborns, 299 though previous findings that OTA exposure is associated with poor birth outcomes and infant 300 growth have been reported inconsistently. In Uganda, AF exposure measured in mid-301 pregnancy was associated with LBW and smaller head circumference (55). Formerly, Jonsyn 302 et al. (1995) also reported that when OTA is present in combination with AFs and their 303 metabolites in cord blood samples, the birth weight is likely to be reduced (47). A study from 304 Ethiopia found an association between chronic maternal AF exposure and lower fetal growth 305 trajectories using fetal biometry from ultrasound estimates. However, the same study did not 306 find an association of AF exposure with birth anthropometry (56). A systematic review of 307 studies that evaluated mycotoxin exposure and infant growth also found inconsistent results 308 (28). With the wide variation in detected mycotoxin concentrations and possible confounding 309 factors adjusted for in these studies, it is not surprising that some found associations and 310 others did not.

311 In contrast, in our previous analysis of OTA exposure during the third trimester of pregnancy 312 in the same cohort, we did not find associations between maternal exposure and growth at 313 birth and at 6 months of age (35). Besides this, we only found a fair level of agreement 314 between maternal OTA exposure during the third trimester of pregnancy (50.8%) and 315 neonatal exposure (38.3%) status (Kappa = 0.27). There was also no constant pattern in the 316 type or quantity of AFs or OTA detected in maternal and cord blood samples in other studies. 317 A study in Sierra Leone detected 12.5% OTA exposure in maternal serum samples versus 318 25.5% in cord blood samples (11); while a study in Bolivia detected OTA in 87% in the cord 319 plasma samples versus 12.5% in the maternal plasma samples (57). A potential reason for the 320 higher detection of OTA in the previous prenatal maternal OTA exposure analysis conducted 321 (35) is that it was conducted at 30-34 weeks of gestation, and previous literature have reported 322 that the level of OTA from the mother to the fetus has a higher transfer rate in the earlier 323 stages of pregnancy compared to later (15). Furthermore, OTA distribution in the human body 324 could also be affected by the development of placenta and physiological differences 325 throughout pregnancy (58). Lastly, there could be seasonal variations in mycotoxin exposure 326 status depending on food availability, and storage conditions with the maternal samples were 327 collected between July and March (35) while the newborn samples were collected between 328 May and October.

In the previous analysis by de Kok *et al.* (2022) maternal BEP supplementation during pregnancy and lactation were beneficial in reducing the prevalence of LBW, and improving GA, birth weight, birth length and chest circumference (59). However, iron and folic acid supplementation in the form of BEP or IFA tablets formulations did not improve anemia prevalence during pregnancy (60). Similarly, there was a high prevalence of infant anemia at 6 months of age in both intervention and control groups (61) suggesting the limited effect of

16

maternal iron and folic acid supplementations in the form of BEP and IFA tablets
formulations. On the other hand, the exploratory analysis here indicated a beneficial role of
BEP in mitigating the negative effect of OTA exposure on increased infant anemia at the age
of 6 months. To our knowledge, there is no other study addressing the role of nutritional
supplementation on the effects of mycotoxins exposure.

340 The high prevalence of OTA exposure in the present study can have severe adverse 341 consequences. After its absorption from the gastrointestinal tract, OTA binds mainly to 342 albumin with high affinity, resulting in its long half-life (62). The OTA mechanism of action is very complex, since it is understood to be carcinogenic, hepatotoxic, immunotoxic, 343 344 neurotoxic and teratogenic, based on in vitro and on animal studies (63,64). In humans, OTA 345 exposure has been associated with the development of Tunisian Nephropathy (65), gastric and 346 esophageal tumors (66,67), as well as testicular cancer (68). Considering the risks posed by 347 mycotoxins in LMICs, Matumba and colleagues (2021) proposed a framework for prevention 348 and control of mycotoxins in grains. The guideline has five pointers including: i) Sustaining 349 plant's strength and health; ii) Reducing toxigenic fungal population in growing plants and in 350 storage; iii) Rapidly reducing moisture content of grains and avoid rehydration; iv) 351 Safeguarding outer structure of seeds/grains and v) Cleaning and removing mycotoxin high 352 risk components. The guideline also provides recommendation on how grains should be 353 handled from production, harvesting and storage practices all the way to processing 354 considering the factors that promote or prevent fungal contamination and subsequent 355 production of mycotoxins in grains (69).

356 Some of the strengths of the present study include determination of GA using ultrasonography 357 and the assessment of birth outcomes within 12 hours of birth, allowing the timely and robust 358 assessment of study outcomes. The determination of mycotoxin exposure using biomarkers is

359 also superior to the assessment in foodstuffs used in some studies (70). This is also the first 360 application of VAMS for mycotoxin analysis in the whole blood of newborns in an LMIC 361 setting. Considering the benefits of VAMS and the robust method developed, VAMS 362 sampling can be considered as an alternative technique to perform a quantitative screening of mycotoxin exposure (42). The findings also provide support for future studies, using larger 363 364 cohorts, with sampling using VAMS. In addition, considering the toxicokinetic profiles of the 365 detected mycotoxins, this microsampling technique will further highlight the effect of 366 exposure to mycotoxins on human health, enabling further associations to be made with 367 adverse health outcomes. Lastly, as a limitation, mycotoxin exposure data from only a single 368 time point postnatally was considered. Future studies, using repeated mycotoxins 369 measurements, will provide an insight into the effects of mycotoxins and their 370 physicochemical properties in relation to the timing of exposure. Moreover, further studies 371 assessing mycotoxin exposure during the complementary feeding period in infants and young 372 children will also provide a full picture of the burden of the problem and its effects during the 373 critical window period in this and similar populations.

In conclusion, this study reports a high occurrence of newborn OTA exposure and an
associated risk of lower birthweight, ponderal index and height growth trajectories in rural
Burkina Faso. The findings emphasize the importance of nutrition-sensitive strategies to
mitigate dietary OTA in the food supply, as well as adopting food safety measures in LMICs
during the fetal period of development.

379 Data availability request

Given the personal nature of the data, data will be made available through a data-sharingagreement. Please contact carl.lachat@ugent.be and marthe.deboevre@ugent.be for any

- 382 queries. Supporting study documents, including the study protocol and questionnaires, are
- 383 publicly available on the study's website: https://misame3.ugent.be (accessed on 07
- 384 December 2023).

385 Statements and Declarations

- 386 Funding
- 387 The MISAME-III main trial work was supported by the Bill & Melinda Gates Foundation
- 388 (OPP1175213). The mycotoxins sampling and analysis was supported by Fonds
- 389 Wetenschappelijk Onderzoek (project No G085921N). MDB was supported by the European
- 390 Research Council under the European Union's Horizon 2020 research and innovation
- 391 program (grant agreement No 946192, HUMYCO). The funders had no role in the design and
- 392 conduct of the study; collection, management, analysis, and interpretation of the data; and
- 393 preparation, review, or approval of the manuscript.

394 Conflicts of interest

395 The authors have no relevant financial or non-financial interests to disclose.

396 Author contributions

- 397 Author Contributions: Author Conceptualization: Y.B.-M., A.A., T.D.-C., S.D.S., CL and
- 398 M.D.B.; Methodology: Y.B-M., J.E-H., S.D.S. and M.D.B.; Software: Y.B.-M., A.A., and
- 399 T.D.-C.; Validation: Y.B-M., G.D.P, J.E-H., S.D.S. and M.D.B.; Formal analysis: Y.B-M
- 400 and A.A.; Investigation: Y.B.-M., G.D.P, T.D.-C, J.E-H., L.O., S.D.S. and M.D.B.;
- 401 Resources: Y.B.-M., T.D.-C., L.O., L.C.T., S.D.S, C.L. and M.D.B.; Data Curation: Y.B.-M.,
- 402 A.A., T.D.-C. and L.O.; Writing—Original Draft: Y.B.-M. and A,A.; Writing—Review and
- 403 Editing: Y.B.-M., A.A., G.D.P, T.D.-C., J.E-H., L.O., L.C.T., S.D.S., C.L and M.D.B.;

- 404 Supervision: T.D.-C., S.D.S, C.L., and M.D.B.; Project Administration: Y.B.-M., T.D.-C.,
- 405 L.O., L.C.T., C.L., S.D.S. and M.D.B.; Funding Acquisition: T.D.-C., C.L. and M.D.B.

406 **Ethical considerations**

- 407 The study protocol was approved by the Ethical Committee of Ghent University Hospital in
- 408 Belgium (B670201734334) and the Ethical Committee of Institut de Recherche en Sciences
- 409 de la Santé in Burkina Faso (50-2020/CEIRES). Written informed consent was obtained from
- 410 all subjects involved in the study.

411 **Consent to participate**

412 Informed consent was obtained from all subjects involved in the study.

413 **Consent for publication**

414 All the authors also agreed on the publication of this article.

415 **References**

- Goessens T, Mouchtaris-Michailidis T, Tesfamariam K, Truong NN, Vertriest F, Bader 416 1. 417 Y, et al. Dietary mycotoxin exposure and human health risks: A protocol for a systematic 418 review. Environ Int [Internet]. 2024 Feb 1 [cited 2024 Feb 2];184:108456. Available 419 from: https://linkinghub.elsevier.com/retrieve/pii/S0160412024000424 420 2. Abiala MA, Ezekiel CN, Chukwura NI, Odebode AC. Toxigenic Aspergillus section 421 Flavi and aflatoxins in Dried Yam Chips in Oyo State, Nigeria. Academia Arena 422 [Internet]. 2011 [cited 2023 Feb 22];(5):3. Available from: http://www.sciencepub.net 423 Ngum NQ, Babalola OO, Ekwomadu TI, Nleya N, Mulunda M. Six Main Contributing 3.
- Factors to High Levels of Mycotoxin Contamination in African Foods. Toxins 2022, Vol
 14, Page 318 [Internet]. 2022 Apr 29 [cited 2022 Jul 1];14(5):318. Available from:
 https://www.mdpi.com/2072-6651/14/5/318/htm
- 427 Aasa AO, Fru FF, Adelusi OA, Oyeyinka SA, Njobeh PB. A review of toxigenic fungi 4. 428 and mycotoxins in feeds and food commodities in West Africa. World Mycotoxin J 429 [Internet]. 2022 Jul 18 2023 [cited Feb 9];1–16. Available from: 430 https://www.wageningenacademic.com/doi/10.3920/WMJ2021.2766
- 431 5. Compaore H, Samandoulougou S, Ware LY, Bambara A, Ratongue H, Sawadogo I, et
 432 al. Identification of Aspergillus section Flavi and Fumigati in maize grown in Burkina
 433 Faso. Int J Biosci [Internet]. 2021 [cited 2023 Dec 21]; Available from:
 434 http://dx.doi.org/10.12692/ijb/18.6.25-36
- Ota E, Ganchimeg T, Morisaki N, Vogel JP, Pileggi C, Ortiz-Panozo E, et al. Risk factors
 and adverse perinatal outcomes among term and preterm infants born small-forgestational-age: secondary analyses of the WHO Multi-Country Survey on Maternal and
 Newborn Health. PLoS One [Internet]. 2014 Aug 13 [cited 2023 Aug 4];9(8). Available
 from: https://pubmed.ncbi.nlm.nih.gov/25119107/

Lee SE, Talegawkar SA, Merialdi M, Caulfield LE. Dietary intakes of women during
pregnancy in low- and middle-income countries [Internet]. Vol. 16, Public Health
Nutrition. 2013. p. 1340–53. Available from:
https://doi.org/10.1017/S1368980012004417

- Abdulrazzaq YM, Osman N, Ibrahim A. Fetal exposure to aflatoxins in the United Arab
 Emirates. Ann Trop Paediatr [Internet]. 2002 [cited 2023 Feb 28];22(1):3–9. Available
 from: https://pubmed.ncbi.nlm.nih.gov/11926047/
- 447 9. Chan-Hon-Tong A, Charles MA, Forhan A, Heude B, Sirot V. Exposure to food
 448 contaminants during pregnancy. Science of The Total Environment. 2013 Aug 1;458–
 449 460:27–35.
- Groopman JD, Egner PA, Schulze KJ, Wu LSF, Merrill R, Mehra S, et al. Aflatoxin
 exposure during the first 1000 days of life in rural South Asia assessed by aflatoxin B1lysine albumin biomarkers. Food and Chemical Toxicology. 2014 Dec 1;74:184–9.
- Jonsyn FE, Maxwell SM, Hendrickse RG. Human fetal exposure to ochratoxin A and
 aflatoxins. Ann Trop Paediatr [Internet]. 1995 [cited 2023 Aug 7];15(1):3–9. Available
 from: https://pubmed.ncbi.nlm.nih.gov/7598434/
- IARC (International Agency for Research on Cancer). Some naturally occurring
 substances: heterocyclic aromatic amines and mycotoxins. IARC Monogr Eval Carcinog
 Risk Chem Hum [Internet]. 1993 [cited 2023 Feb 8];56(October 1982):397–444.
 Available from: https://www.ncbi.nlm.nih.gov/books/NBK513574/
- Godschalk RWL, Kleinjans JCS. Characterization of the exposure-disease continuum in
 neonates of mothers exposed to carcinogens during pregnancy. Basic Clin Pharmacol
 Toxicol. 2008 Feb;102(2):109–17.

- 463 14. Lombard MJ. Mycotoxin Exposure and Infant and Young Child Growth in Africa: What
- 464 Do We Know? Ann Nutr Metab [Internet]. 2014 Oct 1 [cited 2023 Nov 8];64(Suppl.
- 465 2):42–52. Available from: https://dx.doi.org/10.1159/000365126
- 466 15. Woo CSJ, Partanen H, Myllynen P, Vähäkangas K, El-Nezami H. Fate of the teratogenic
 467 and carcinogenic ochratoxin A in human perfused placenta. Toxicol Lett. 2012 Jan
- 468 5;208(1):92–9.
- Coronel MB, Sanchis V, Ramos AJ, Marin S. Review. Ochratoxin A: presence in human
 plasma and intake estimation. Food Sci Technol Int [Internet]. 2010 Feb [cited 2023 Feb
- 471 13];16(1):5–18. Available from: https://pubmed.ncbi.nlm.nih.gov/21339117/
- 472 17. Bunge I, Dirheimer G, Röschenthaler R. In vivo in vitroinhibition of protein synthesis in
 473 Bacillus stearothermophilus by ochratoxin A. Biochem Biophys Res Commun. 1978 Jul
 474 28;83(2):398–405.
- 475 18. Konrad I, Röschenthaler R. Inhibition of phenylalanine tRNA synthetase from Bacillus
 476 subtilis by ochratoxin A. FEBS Lett. 1977 Nov 15;83(2):341–7.
- Arce-López B, Lizarraga E, Vettorazzi A, González-Peñas E. Human Biomonitoring of 477 19. 478 Mycotoxins in Blood, Plasma and Serum in Recent Years: A Review. Toxins (Basel) 479 2020 [cited 2023 2];12(3). Available [Internet]. Oct from: 480 https://pubmed.ncbi.nlm.nih.gov/32121036/
- Ali N, Hossain K, Degen GH. Blood plasma biomarkers of citrinin and ochratoxin A
 exposure in young adults in Bangladesh. Mycotoxin Res [Internet]. 2018 Mar 1 [cited
 2023 Sep 13];34(1):59–67. Available from:
 https://link.springer.com/article/10.1007/s12550-017-0299-5
- 485 21. Fan K, Xu J, Jiang K, Liu X, Meng J, Di Mavungu JD, et al. Determination of multiple
 486 mycotoxins in paired plasma and urine samples to assess human exposure in Nanjing,
 487 China. Environmental Pollution. 2019 May 1;248:865–73.

- 488 22. Karima HK, Ridha G, Zied A, Chekib M, Salem M, Abderrazek H. Estimation of
 489 Ochratoxin A in human blood of healthy Tunisian population. Experimental and
 490 Toxicologic Pathology. 2010 Sep 1;62(5):539–42.
- 491 23. Tesfamariam K, Argaw A, Hanley-Cook GT, Gebreyesus SH, Kolsteren P, Belachew T,
- 492 et al. Multiple mycotoxin exposure during pregnancy and risks of adverse birth
 493 outcomes: a prospective cohort study in rural Ethiopia. Environ Int [Internet]. 2022 Feb
 494 [cited 2022 Jan 18];160:107052. Available from:
 495 https://linkinghub.elsevier.com/retrieve/pii/S0160412021006772
- 496 24. Etzel RA, Zilber JJ. Reducing Malnutrition: Time to Consider Potential Links Between
 497 Stunting and Mycotoxin Exposure? Pediatrics [Internet]. 2014 Jul 1 [cited 2023 Aug
 498 7];134(1):4–6. Available from: /pediatrics/article/134/1/4/62292/Reducing499 Malnutrition-Time-to-Consider-Potential
- 500 25. Christian P, Lee SE, Angel MD, Adair LS, Arifeen SE, Ashorn P, et al. Risk of childhood
 501 undernutrition related to small-for-gestational age and preterm birth in low- and middle502 income countries. Int J Epidemiol [Internet]. 2013 Oct [cited 2024 Feb 15];42(5):1340–
- 503 55. Available from: https://pubmed.ncbi.nlm.nih.gov/23920141/
- 504 Gu H, Wang L, Liu L, Luo X, Wang J, Denis Nkomola P, et al. A gradient relationship 26. 505 between low birth weight and IQ: A meta-analysis OPEN. SCiEnTifiC RepoRtS | 506 [Internet]. 2017 [cited 2024 Feb 15];7:18035. Available from: 507 www.nature.com/scientificreports/
- Jornayvaz FR, Vollenweider P, Bochud M, Mooser V, Waeber G, Marques-Vidal P. Low
 birth weight leads to obesity, diabetes and increased leptin levels in adults: the CoLaus
 study. Cardiovasc Diabetol. 2016;15:73.
- 511 28. Tesfamariam K, De Boevre M, Kolsteren P, Belachew T, Mesfin A, De Saeger S, et al.
 512 Dietary mycotoxins exposure and child growth, immune system, morbidity, and

- mortality: a systematic literature review. Crit Rev Food Sci Nutr [Internet]. 2020 Oct 27
 [cited 2023 Oct 13];60(19):3321–41. Available from:
 https://pubmed.ncbi.nlm.nih.gov/31694387/
- 516 29. Kyei NNA, Boakye D, Gabrysch S. Maternal mycotoxin exposure and adverse 517 pregnancy outcomes: a systematic review. Mycotoxin Res [Internet]. 2020 May 1 [cited
- 518 2023 Aug 14];36(2):243–55. Available from:
- 519 https://pubmed.ncbi.nlm.nih.gov/31989413/
- 30. Gönenç İM, Yilmaz Sezer N, Yilmaz S. Mycotoxin exposure and pregnancy. Crit Rev
 Toxicol [Internet]. 2020 Aug 8 [cited 2023 Oct 18];50(7):594–604. Available from:
 https://www.tandfonline.com/doi/abs/10.1080/10408444.2020.1803791
- 31. Hassen JY, Debella A, Eyeberu A, Mussa I. Level of exposure to aflatoxins during
 pregnancy and its association with adverse birth outcomes in Africa: a meta-analysis. Int
 Health [Internet]. 2024 Feb 10 [cited 2024 Feb 15];0:1–15. Available from:
 https://dx.doi.org/10.1093/inthealth/ihae015
- 527 32. Kpoda DS, Bandé M, Ouattara AS, Bazié RBS, Compaoré AM, Meda RN, et al.
 528 Nutritional, Microbiological, and Toxicological Quality Assessment of Foods Sold in
 529 Urban and Suburban Markets in Burkina Faso. https://home.liebertpub.com/hs
 530 [Internet]. 2022 Aug 11 [cited 2023 Apr 21];20(4):298–307. Available from:
 531 https://www.liebertpub.com/doi/10.1089/hs.2022.0023
- 532 33. FAO. Worldwide regulations for mycotoxins in food and feed in 2003 [Internet]. 2003
 533 [cited 2022 Jul 1]. Available from: https://www.fao.org/3/y5499e/y5499e0d.htm
- 534 34. Warth B, Parich A, Atehnkeng J, Bandyopadhyay R, Schuhmacher R, Sulyok M, et al.
- 535 Quantitation of Mycotoxins in Food and Feed from Burkina Faso and Mozambique
- 536 Using a Modern LC-MS/MS Multitoxin Method. 2012 [cited 2022 Jul 1]; Available
- 537 from: https://pubs.acs.org/sharingguidelines

538 35. Bastos-Moreira Y, Argaw A, Dailey-Chwalibóg T, El-Hafi J, Ouédraogo LO, Toe LC,

- 539 et al. Prenatal ochratoxin A exposure, birth outcomes and infant growth in rural Burkina
- 540 Faso: a human biomonitoring sub-study from the MISAME-III trial. medRxiv [Internet].
- 541 2024 Feb 24 [cited 2024 Feb 26];460:2024.02.23.24303256. Available from:
- 542 https://www.medrxiv.org/content/10.1101/2024.02.23.24303256v1
- 543 36. Vanslambrouck K, De Kok B, Toe LC, De Cock N, Ouedraogo M, Dailey-Chwalibóg T,
 544 et al. Effect of balanced energy-protein supplementation during pregnancy and lactation
 545 on birth outcomes and infant growth in rural Burkina Faso: study protocol for a
 546 randomised controlled trial. BMJ Open [Internet]. 2021 Mar 24 [cited 2023 Nov
 547 8];11(3). Available from: https://pubmed.ncbi.nlm.nih.gov/33762226/
- 548 37. Bastos-Moreira Y, Ouédraogo L, De Boevre M, Argaw A, de Kok B, Hanley-Cook GT,
- et al. A Multi-Omics and Human Biomonitoring Approach to Assessing the
 Effectiveness of Fortified Balanced Energy–Protein Supplementation on Maternal and
 Newborn Health in Burkina Faso: A Study Protocol. Nutrients 2023, Vol 15, Page 4056
 [Internet]. 2023 Sep 19 [cited 2023 Nov 8];15(18):4056. Available from:
 https://www.mdpi.com/2072-6643/15/18/4056/htm
- de Kok B, Moore K, Jones L, Vanslambrouck K, Toe LC, Ouédraogo M, et al. Home
 consumption of two fortified balanced energy protein supplements by pregnant women
 in Burkina Faso. Matern Child Nutr. 2021;17(3):1–13.
- 39. Hanley-Cook G, Argaw A, de Kok B, Toe LC, Dailey-Chwalibóg T, Ouédraogo M, et
 al. Seasonality and Day-to-Day Variability of Dietary Diversity: Longitudinal Study of
 Pregnant Women Enrolled in a Randomized Controlled Efficacy Trial in Rural Burkina
 Faso. Journal of Nutrition. 2022;152(9):2145–54.
- 561 40. Villar J, Ismail LC, Victora CG, Ohuma EO, Bertino E, Altman DG, et al. International
 562 standards for newborn weight, length, and head circumference by gestational age and

- sex: the Newborn Cross-Sectional Study of the INTERGROWTH-21st Project. The
 Lancet. 2014 Sep;384(9946):857–68.
- 56541.de Onis M, Branca F. Childhood stunting: a global perspective. Matern Child Nutr566[Internet]. 2016 May 1 [cited 2023 May 16];12 Suppl 1(Suppl 1):12–26. Available from:
- 567 https://pubmed.ncbi.nlm.nih.gov/27187907/
- Vidal A, Belova L, Stove C, De Boevre M, De Saeger S. Volumetric Absorptive
 Microsampling as an Alternative Tool for Biomonitoring of Multi-Mycotoxin Exposure
 in Resource-Limited Areas. Toxins (Basel) [Internet]. 2021 [cited 2021 Nov 10];13(5).
- 571 Available from: /pmc/articles/PMC8150583/
- 572 43. Viera A, Garrett J. Understanding interobserver agreement: the kappa statistic. Fam Med.
 573 2005;
- 57444.Pfohl-Leszkowicz A, Manderville RA. Ochratoxin A: An overview on toxicity and575carcinogenicity in animals and humans. Mol Nutr Food Res [Internet]. 2007 Jan [cited5762023Aug17];51(1):61–99.Availablefrom:
- 577 https://pubmed.ncbi.nlm.nih.gov/17195275/
- Jørgensen K. Occurrence of ochratoxin A in commodities and processed food--a review of EU occurrence data. Food Addit Contam [Internet]. 2005 Jan [cited 2024 Feb 7];22
 Suppl 1(SUPPL. 1):26–30. Available from: https://pubmed.ncbi.nlm.nih.gov/16332618/
 Somda MK, Dabire Y, Mogmenga I, Ouattara A, Nikiema M, Mihin HB, et al. Assessment of Maize Contamination by Aflatoxin in Burkina Faso: A Review of Methods of Control. Food Nutr Sci [Internet]. 2023 [cited 2023 Apr 21];14:135–47.
- 584 Available from: https://doi.org/10.4236/fns.2023.142010
- Jonsyn FE, Maxwell SM, Hendrickse RG. Ochratoxin A and aflatoxins in breast milk
 samples from Sierra Leone. Mycopathologia [Internet]. 1995 Aug [cited 2024 Feb
 7];131(2):121–6. Available from: https://link.springer.com/article/10.1007/BF01102890

Mahdavi R, Nikniaz L, Arefhosseini SR, Vahed Jabbari M. Determination of aflatoxin
M(1) in breast milk samples in Tabriz-Iran. Matern Child Health J [Internet]. 2010 Jan
[cited 2023 Oct 13];14(1):141–5. Available from:
https://pubmed.ncbi.nlm.nih.gov/19093194/

- 49. Lauer JM, Natamba BK, Ghosh S, Webb P, Wang JS, Griffiths JK. Aflatoxin exposure
 in pregnant women of mixed status of human immunodeficiency virus infection and rate
 of gestational weight gain: a Ugandan cohort study. Tropical Medicine and International
 Health. 2020 Sep 1;25(9):1145–54.
- 596 50. McCormick SP, Kato T, Maragos CM, Busman M, Lattanzio VMT, Galaverna G, et al.
- Anomericity of T-2 toxin-glucoside: Masked mycotoxin in cereal crops. J Agric Food
 Chem [Internet]. 2015 Jan 21 [cited 2023 Oct 22];63(2):731–8. Available from:
 https://pubs.acs.org/doi/full/10.1021/jf504737f
- 51. Patil RD, Dwivedi P, Sharma AK. Critical period and minimum single oral dose of
 ochratoxin A for inducing developmental toxicity in pregnant Wistar rats. Reproductive
 Toxicology. 2006 Nov 1:22(4):679–87.
- Moré J, Galtier P, Alvinerie M, Escribe MJ. Effet embryotoxique et tératogène chez le
 rat. Annales de Recherches Vétérinaires [Internet]. 1974 [cited 2024 Feb 9];5(2):167–
 78. Available from: https://hal.science/hal-00900797
- 53. Moré J, Galtier P, Alvinerie M, Brunel-Dubech N. TOXICITE DE L'OCHRATOXINE
- A. 3. EFFETS PENDANT LES STADES INITIAUX DE LA GESTATION CHEZ LE
- 608 RAT TOXICITE DE L'OCHRATOXINE A 3. EFFETS PENDANT LES STADES
- 609 INITIAUX DE LA GESTATION CHEZ LE RAT. Annales de Recherches Vétérinaires
- 610 [Internet]. 1978 [cited 2024 Feb 8]; Available from: https://hal.science/hal-00900988
- 611 54. Moré J, Galtier P, Brunel-Dubech N, Alvinerie M, Descendance F S LA, RATTFS
- 612 INTOXIQUÉES MORÉ P GALTIER Nicole BRUNEL-DUBECH M ALVINERIE DJ.

- Effets du traitement sur la descendance (F1 et F2) des rates intoxiqu'ees. Annales de
 Recherches Vétérinaires [Internet]. 1975 [cited 2024 Feb 9];6(4):379–89. Available
 from: https://hal.science/hal-00900858
- 55. Lauer JM, Duggan CP, Ausman LM, Griffiths JK, Webb P, Wang JS, et al. Maternal
 aflatoxin exposure during pregnancy and adverse birth outcomes in Uganda. Matern
- 618 Child Nutr. 2019 Apr 1;15(2):e12701.
- 619 56. Tesfamariam K, Gebreyesus SH, Lachat C, Hanley-Cook GT, Roro M, Mengistu YG, et 620 al. Chronic aflatoxin exposure during pregnancy is associated with lower fetal growth 621 trajectories: a prospective cohort from the Butajira Nutrition, Mental Health, and 622 Pregnancy (BUNMAP) Study in rural Ethiopia. Am J Clin Nutr [Internet]. 2022 Dec 1 623 [cited 2023 Oct 18];116(6):1634-41. Available from: 624 https://pubmed.ncbi.nlm.nih.gov/36178051/
- 57. Ferrufino-Guardia E, Chavez-Rico V, Larondelle Y. Ochratoxin a in human breast milk,
 maternal and placental blood from Cochabamba-Bolivia. 2019 [cited 2024 Feb 20];
 Available from: https://www.redalyc.org/articulo.oa?id=91967023005
- 58. Zimmerli B, Dick R. Determination of ochratoxin A at the ppt level in human blood,
 serum, milk and some foodstuffs by high-performance liquid chromatography with
 enhanced fluorescence detection and immunoaffinity column cleanup: methodology and
 Swiss data. J Chromatogr B Biomed Sci Appl. 1995 Apr 7;666(1):85–99.
- 632 de Kok B, Toe LC, Hanley-Cook G, Argaw A, Ouédraogo M, Compaoré A, et al. 59. Prenatal fortified balanced energy-Protein supplementation and birth outcomes in rural 633 634 Burkina Faso: A randomized controlled efficacy trial. PLoS Med [Internet]. 2022 May 13 [cited 635 2022 19];19(5):e1004002. Available from: Aug 636 https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1004002

Hanley-Cook G, Toe LC, Tesfamariam K, de Kok B, Argaw A, Compaoré A, et al. 637 60. Fortified Balanced Energy-Protein Supplementation, Maternal Anemia, and Gestational 638 639 Weight Gain: a Randomized Controlled Efficacy Trial Among Pregnant Women in Rural 640 Burkina Faso. J Nutr [Internet]. 2022 Jul 30 [cited 2022 Sep 22]; Available from: https://academic.oup.com/jn/advance-article/doi/10.1093/jn/nxac171/6652215 641 642 61. Argaw A, de Kok B, Toe LC, Hanley-Cook G, Dailey-Chwalibóg T, Ouédraogo M, et al. Fortified balanced energy-protein supplementation during pregnancy and lactation 643 644 and infant growth in rural Burkina Faso: A 2×2 factorial individually randomized controlled trial. PLoS Med [Internet]. 2023 Feb 1 [cited 2023 Apr 20];20(2):e1004186. 645 646 Available from: 647 https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1004186 648 62. Kőszegi T, Poór M. Ochratoxin A: Molecular Interactions, Mechanisms of Toxicity and Prevention at the Molecular Level. Toxins 2016, Vol 8, Page 111 [Internet]. 2016 Apr 649 650 15 [cited 2023 Oct 12];8(4):111. Available from: https://www.mdpi.com/2072-651 6651/8/4/111/htm 652 el Khoury AE, Atoui A. Ochratoxin A: General Overview and Actual Molecular Status. 63. Toxins 2010, Vol 2, Pages 461-493 [Internet]. 2010 Mar 29 [cited 2023 Oct 653 654 12];2(4):461–93. Available from: https://www.mdpi.com/2072-6651/2/4/461/htm 655 64. Ringot D, Chango A, Schneider YJ, Larondelle Y. Toxicokinetics and toxicodynamics 656 of ochratoxin A, an update. Chem Biol Interact. 2006 Jan 5;159(1):18-46. 65. Hassen W, Abid-Essafi S, Achour A, Guezzah N, Zakhama A, Ellouz F, et al. 657

Karyomegaly of tubular kidney cells in human chronic interstitial nephropathy in
Tunisia: respective role of Ochratoxin A and possible genetic predisposition. Hum Exp
Toxicol [Internet]. 2004 Jul [cited 2023 Oct 12];23(7):339–46. Available from:
https://pubmed.ncbi.nlm.nih.gov/15311851/

- 662 66. Cui J, Xing L, Li Z, Wu S, Wang J, Liu J, et al. Ochratoxin A induces G(2) phase arrest
 663 in human gastric epithelium GES-1 cells in vitro. Toxicol Lett [Internet]. 2010 Mar 15
 664 [cited 2023 Oct 12];193(2):152–8. Available from:
 665 https://pubmed.ncbi.nlm.nih.gov/20060447/
- 666 67. Liu J, Wu S, Shen H, Cui J, Wang Y, Xing L, et al. Ochratoxin A induces DNA damage
- and G2 phase arrest in human esophageal epithelium Het-1A cells in vitro. J Toxicol Sci
 [Internet]. 2015 Sep 10 [cited 2023 Oct 12];40(5):657–65. Available from:
 https://pubmed.ncbi.nlm.nih.gov/26354382/
- 670 68. Schwartz GG. Hypothesis: does ochratoxin A cause testicular cancer? Cancer Causes
 671 Control [Internet]. 2002 [cited 2023 Oct 12];13(1):91–100. Available from:
 672 https://pubmed.ncbi.nlm.nih.gov/11899122/
- 673 69. Matumba L, Namaumbo S, Ngoma T, Meleke N, De Boevre M, Logrieco AF, et al. Five
 674 keys to prevention and control of mycotoxins in grains: A proposal. Glob Food Sec. 2021
 675 Sep 1:30:100562.
- 676 70. De Boevre M, Jacxsens L, Lachat C, Eeckhout M, Di Mavungu JD, Audenaert K, et al.
- Human exposure to mycotoxins and their masked forms through cereal-based foods in
 Belgium. Toxicol Lett. 2013 Apr 26;218(3):281–92.

679

Table 1. Characteristics of study participants

Characteristics	All subjects (n=274)	OTA unexposed (n = 169)	OTA exposed (n = 105)
Study health center catchment area			
Boni	43 (15.7)	29 (17.2)	14 (13.3)
Dohoun	35 (12.8)	20 (11.8)	15 (14.3)
Dougoumato II	46 (16.8)	22 (13.0)	24 (22.9)
Karaba	37 (13.5)	18 (10.7)	19 (18.1)
Kari	58 (21.2)	41 (24.3)	17 (16.2)
Koumbia	55 (20.1)	39 (23.1)	16 (15.2)
Household level			
Wealth index, 0 to 10 points	4.70 ± 1.78	4.80 ± 1.75	4.54 ± 1.83
Household food insecurity ^a	192 (70.3)	111(65.7)	81 (77.9)
Improved primary water source ^b	162 (59.1)	102 (60.4)	60 (57.1)
Improved sanitation facility ^c	174 (63.5)	105 (62.1)	69 (65.7)
Household size	6.47 ± 4.64	6.64 ± 4.75	6.18 ± 4.47
Maternal factors			
Age, years	24.26 ± 5.63		
Ethnic group			
Bwaba	156 (56.9)	99 (58.6)	57 (54.3)
Mossi	88 (32.1)	54 (32.0)	34 (32.4)
Others	30 (11.0)	16 (9.4)	14 (13.3)
Religion pregnant women			
Muslim	119 (43.4)	71 (42.0)	48 (45.7)
Protestant	64 (23.4)	35 (20.7)	29 (27.6)
Animist	62 (22.6)	48 (28.4)	14 (13.3)
Catholic	22 (8.0)	11 (6.5)	11 (10.5)
No religion, no animist	5 (1.8)	3 (1.8)	2 (1.9)
Primary education and above	124 (45.3)	80 (48.2)	44 (41.9)
Trimester of pregnancy at enrollment			
First	219 (79.9)	139 (82.2)	80 (76.2)
Second	55 (20.1)	30 (17.8)	25 (23.8)
Parity			
0	69 (25.2)	38 (22.5)	31 (29.5)
1 to 2	105 (38.3)	76 (45.0)	29 (27.6)
≥3	100 (36.5)	55 (32.5)	45 (42.9)
Weight, kg	58.40 ± 9.67	59.24 ± 9.81	57.03 ± 9.32
Height, cm	162.47 ± 5.73	163.01 ± 5.35	161.61 ± 6.23
BMI, kg/m ²	22.09 ± 3.22	22.27 ± 3.34	21.79 ± 3.01
MUAC, mm	261.6 ± 27.9	262.6 ± 28.8	260.0 ± 26.3
Hemoglobin, g/dL	11.69 ± 1.45	11.76 ± 1.42	11.58 ± 1.49
Anemia (Hb < 11 g/dL)	82 (29.9)	47 (27.8)	35 (33.3)
Maternal prenatal supplementation			
BEP + IFA	142 (46.0)	81 (47.9)	44 (41.9)
IFA	167 (54.1)	88 (52.1)	61 (58.1)
Maternal postnatal supplementation			
BEP + IFA	156 (50.5)	94 (55.6)	50 (47.6)
IFA	153 (49.5)	75 (44.4)	55 (52.4)

Data are frequencies (%) or means \pm SD.

^aAssessed using FANTA/USAID's Household Food Insecurity Access Scale.

^bProtected well, borehole, pipe, or bottled water were considered improved water sources.

^cFlush toilet connected to local sewage or septic tank or pit latrine with slab and/or ventilation were considered improved sanitation facilities. ^dHeight of one woman with a physical disability could not be measured.

^e An average food group diversity score was computed from the list-based recalls collected on different days throughout the entire pregnancy. BEP, balanced energy-protein; IFA, iron-folic acid; BMI, body mass index; HB, hemoglobin; MUAC, mid-upper arm circumference; OTA, ochratoxin A.

Table 2. Newborn mycotoxin exposure at birth

Mycotoxins	Positive samples: n (%)	Median (range) µg/L
15-acetyldeoxynivalenol	0.00	<lod (<lod,="" <lod)<="" td=""></lod>
3-acetyldeoxynivalenol	0.00	<lod (<lod,="" <lod)<="" td=""></lod>
aflatoxin B1	1 (0.36)	<lod (<lod,="" 0.34)<="" td=""></lod>
aflatoxin B2	0.00	<lod (<lod,="" <lod)<="" td=""></lod>
aflatoxin G1	6 (2.19)	<lod (<lod,="" 0.31)<="" td=""></lod>
aflatoxin G2	0.00	<lod (<lod,="" <lod)<="" td=""></lod>
aflatoxin M1	2 (0.73)	<lod (<lod,="" 0.7)<="" td=""></lod>
alpha-zearalenol	0.00	<lod (<lod,="" <lod)<="" td=""></lod>
alternariol	0.00	<lod (<lod,="" <lod)<="" td=""></lod>
alternariol monomethyl ether	0.00	<lod (<lod,="" <lod)<="" td=""></lod>
beauvericin	0.00	<lod (<lod,="" <lod)<="" td=""></lod>
beta- zearalenol	0.00	<lod (<lod,="" <lod)<="" td=""></lod>
citrinin	3 (1.1)	<lod (<lod,="" 18.73)<="" td=""></lod>
cyclopiazonic acid	0.00	<lod (<lod,="" <lod)<="" td=""></lod>
deepoxy- deoxynivalenol	0.00	<lod (<lod,="" <lod)<="" td=""></lod>
deoxynivalenol -3- glucoside	0.00	<lod (<lod,="" <lod)<="" td=""></lod>
deoxynivalenol	2 (0.73)	<lod (<lod,="" 0.74)<="" td=""></lod>
diacetoxyscirpenol	0.00	<lod (<lod,="" <lod)<="" td=""></lod>
enniatin A	0.00	<lod (<lod,="" <lod)<="" td=""></lod>
enniatin A1	0.00	<lod (<lod,="" <lod)<="" td=""></lod>
enniatin B	0.00	<lod (<lod,="" <lod)<="" td=""></lod>
enniatin B1	0.00	<lod (<lod,="" <lod)<="" td=""></lod>
fumonisin B1	0.00	<lod (<lod,="" <lod)<="" td=""></lod>
fumonisin B2	0.00	<lod (<lod,="" <lod)<="" td=""></lod>
fumonisin B3	0.00	<lod (<lod,="" <lod)<="" td=""></lod>
fusarenone-X	0.00	<lod (<lod,="" <lod)<="" td=""></lod>
neosolaniol	0.00	<lod (<lod,="" <lod)<="" td=""></lod>
nivalenol	0.00	<lod (<lod,="" <lod)<="" td=""></lod>
ochratoxin A	105 (38.32)	<lod (<lod,="" 3.61)<="" td=""></lod>
ochratoxin alpha	0.00	<lod (<lod,="" <lod)<="" td=""></lod>
roquefortine-C	0.00	<lod (<lod,="" <lod)<="" td=""></lod>
sterigmatocystine	0.00	<lod (<lod,="" <lod)<="" td=""></lod>
T-2-toxin	0.00	<lod (<lod,="" <lod)<="" td=""></lod>
zearalanone	1 (0.36)	<lod (<lod,="" 4.54)<="" td=""></lod>
zearalenone	11 (4.01)	<lod (<lod,="" 4.94)<="" td=""></lod>
LOD, limit of detection		

Outcomes	OTA unexposed (n = 169)	OTA exposed (n = 105)	Unadjusted beta (95% CI)	р	Adjusted beta (95% CI)	р
Birthweight, kg	3.10 ± 0.44	2.95 ± 0.41	-0.15 (-0.26, -0.04)	0.006	-0.11 (-0.21, 0.00)	0.042
Low birthweight (<2.5 kg)	14 (8.28)	17 (16.19)	6.19 (-1.69, 14.1)	0.123	4.79 (3.28, 12.9)	0.243
Small-for-gestational age	35 (20.71)	34 (32.38)	10.8 (-0.41, 22.0)	0.059	7.80 (-3.33, 18.9)	0.169
Gestational age, week	40.09 ± 1.20	39.84 ± 1.27	-0.23 (-0.54, 0.07)	0.141	-0.18 (-0.49, 0.12)	0.236
Preterm delivery (<37 week)	3 (1.78)	2 (1.90)	0.09 (-3.26, 3.43)	0.959	-0.17 (-3.85, 3.51)	0.926
Birth length, cm	48.73 ± 2.06	48.49 ± 1.94	-0.38 (-0.86, 0.11)	0.125	-0.18 (-0.67, 0.30)	0.453
MUAC, mm	101.40 ± 8.24	99.59 ± 8.83	-2.27 (-4.26, -032)	0.023	-1.71 (-3.6, 0.18)	0.077
Head circumference, cm	33.43 ± 1.51	33.39 ± 1.38	-0.15 (-0.49, 0.20)	0.403	-0.07 (-0.41, 0.27)	0.705
Ponderal index, gm/cm ³	26.68 ± 2.38	25.80 ± 2.48	-0.66 (-1.24, -0.09)	0.023	-0.62 (-1.19, -0.05)	0.034
Chest circumference, cm	32.13 ± 1.62	31.76 ± 1.63	-0.41 (-0.82, -0.01)	0.046	-0.28 (-0.67, 0.11)	0.158

 1 Values are mean \pm SD or frequencies (percentages). Unadjusted and adjusted beta coefficients are estimated using linear regression models for the continuous outcomes and linear probability models with robust variance estimation for the binary outcomes. All models are adjusted for the health center catchment areas and the prenatal and postnatal interventions arms, while adjusted models additionally contained maternal age, primiparity, baseline BMI and heamoglobin concentration, and household size, wealth index score, access to improved water and sanitation, and food security status. MUAC, mid-upper arm circumference; OTA, ochratoxin A

Outcomes	OTA unexposed (n 169)	= OTA exposed (n = 105)	Unadjusted beta (95% CI)	р	Adjusted beta (95% CI)	р
Length-for-age Z-score	-0.40 ± 1.12	-0.70 ± 1.17	-0.33 (-0.63, -0.03)	0.031	-0.25 (-0.55, 0.05)	0.105
Weight-for-age Z-score	-0.34 ± 1.07	-0.62 ± 0.99	-0.22 (-0.50, 0.53)	0.113	-0.17 (-045, 0.10)	0.218
Weight-for-length Z-score	-0.03 ± 1.03	-0.20 ± 1.02	-0.08 (-0.34, 0.19)	0.569	-0.07 (-033, 0.20)	0.607
MUAC, mm	141.11 ± 11.29	139.08 ± 12.50	-2.42 (-5.17, 0.33)	0.085	-2.18 (-4.97, 0.61)	0.125
Head circumference, cm	421.14 ± 15.75	417.84 ± 13.65	-3.37 (-7.18, 0.44)	0.083	-2.90 (-6.76, 0.96)	0.14
Hemoglobin, g/dL	10.32 ± 1.31	10.31 ± 1.14	-0.21 (-0.52, 0.10)	0.187	-0.20 (-0.52, 0.11)	0.204
Stunting	13 (8.23)	10 (10.20)	0.68 (-6.81, 8.16)	0.859	-0.11 (-8.23, 8.00)	0.978
Underweight	7 (4.43)	7 (7.22)	2.00 (-4.53, 8.54)	0.546	2.19 (-4.82, 9.20)	0.539
Wasting	3 (1.90)	3 (3.09)	1.28 (-2.74, 5.30)	0.531	1.53 (-2.57, 5.63)	0.464
Anemia	108 (69.23)	67 (70.53)	6.74 (-4.93, 18.4)	0.257	6.79 (-4.87, 18.4)	0.252

Table 4. Newborn ochratoxin A exposure and infant growth and nutritional status at 6 months of age¹

 1 Values are mean \pm SD or frequencies (percentages). Unadjusted and adjusted betas are estimated using linear regression models for the continuous outcomes and linear probability models with robust variance estimation for the binary outcomes. All models are adjusted for the health center catchment areas and the prenatal and postnatal interventions arms, while adjusted models additionally contained maternal age, primiparity, baseline BMI and heamoglobin concentration, and household size, wealth index score, access to improved water and sanitation, and food security status. MUAC, mid-upper arm circumference; OTA, ochratoxin A.



Figure 1. Study flow diagram of the Biospecimen sub-study (BioSpé) of the MISAME-III project.



Figure 2: Infant growth trajectories from birth to 6 months in OTA unexposed (solid lines; n = 169) and exposed (dashed lines; n = 105) groups. Mixed-effects models with random intercept for the individual infant and random slope for the child age were fitted to compare OTA exposed and unexposed groups by growth trajectories during first 6 months postpartum. Quadratic models were used for the outcomes height, weight and MUAC and restricted cubic spline model with 4 knots for the outcome head circumference. Fixed effects in the models contained main effect of time, OTA exposure status and time by exposure interaction, which the later evaluates the difference in monthly growth trajectories between exposed and unexposed groups. Additional covariates in the models included the health center catchment areas, the prenatal and postnatal interventions allocation, maternal age, primiparity, baseline BMI and heamoglobin concentration, and household size, wealth index score, access to improved water and sanitation, and food security status. MUAC, mid-upper arm circumference; OTA, ochratoxin A.



b





Figure 3. UPLC-MS/MS chromatograms of (A) OTA standard solution 2 µg/L; (B) OTA-naturally contaminated whole blood microsample (concentration 0.89 µg/L); (C) OTA-free whole blood microsample.

Outcomes	OTA unexposed	OTA exposed	Unadj beta (95% CI)	р	Adj beta (95% CI)	р
Overall sample (n = 251)				0.070^{2}		0.074 ²
Anemia	108 (69.2)	67 (70.5)	6.74 (-4.93, 18.4)	0.257	6.79 (-4.87, 18.4)	0.252
IFA group (n = 135)						
Anemia	57 (69.5)	42 (79.3)	16.3 (0.95, 31.6)	0.038	18.7 (2.00, 35.3)	0.029
BEP + IFA group (n = 116)						
Anemia	51 (68.9)	25 (59.5)	-4.01 (-21.8, 13.8)	0.657	0.08 (-19.1, 19.3)	0.993

Supplemental Table 1: Infant anemia status at 6 months of age by OTA exposure status for the whole study sample and by maternal prenatal supplementation groups¹

¹Linear probability models with robust variance estimation were used to determine the adjusted and unadjusted differences in anemia status in percentage points and their associated p-values. In the model analyzing the overall sample, the interaction between OTA exposure and the maternal prenatal nutritional supplementation was evaluated by introducing interaction terms with p-values² <0.10 considered as significant interactions. All models are adjusted for the health center catchment areas and the prenatal and postnatal interventions arms, while adjusted models additionally contained maternal age, primiparity, baseline BMI and hemoglobin concentration, and household size, wealth index score, access to improved water and sanitation, and food security status. BEP, balanced energy-protein; IFA, iron-folic acid; OTA, ochratoxin A

STROBE Statement—Checklist of items that should be included in reports of cohort studies

	Item		Page No
	No	Recommendation	
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the	l (Lines 1-2)
		abstract	
		(b) Provide in the abstract an informative and balanced summary of what was done	2
		and what was found	5 (Lines 33-55)
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being	5-6 (Lines 59-87)
		reported	(Lines 55-67)
Objectives	3	State specific objectives, including any prespecified hypotheses	6 (Lines 88-94)
Mothoda			(Lines 66)+)
Study design	4	Present key elements of study design early in the paper	6-10
Setting	5	Describe the setting, locations, and relevant dates, including periods of	6-9
		recruitment, exposure, follow-up, and data collection	
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of	6-9
		participants. Describe methods of follow-up	
		(b) For matched studies, give matching criteria and number of exposed and	N/A
		unexposed	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and	7-9 (Lines 121, 155)
		effect modifiers. Give diagnostic criteria, if applicable	(Lines 121-133)
Data sources/	8*	For each variable of interest, give sources of data and details of methods of	6-11
measurement		assessment (measurement). Describe comparability of assessment methods if there	
		is more than one group	
Bias	9	Describe any efforts to address potential sources of bias	N/A
Study size	10	Explain how the study size was arrived at	N/A
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable,	N/A
		describe which groupings were chosen and why	

Statistical methods		12 (a) Describe all statistical methods, including those used to control for confounding	10-12 (Lines 187-221)
		(b) Describe any methods used to examine subgroups and interactions	10.12
		(b) Describe any methods used to examine subgroups and interactions	(Lines 187-221)
		(c) Explain how missing data were addressed	N/A
		(d) If applicable, explain how loss to follow-up was addressed	N/A
		(\underline{e}) Describe any sensitivity analyses	N/A
Results			
Participants		13* (a) Report numbers of individuals at each stage of study—eg numbers potentially	12 (Lines 224-229)
		eligible, examined for eligibility, confirmed eligible, included in the study,	
		completing follow-up, and analysed	
		(b) Give reasons for non-participation at each stage	N/A
		(c) Consider use of a flow diagram	12 (Lines 224-225)
Descriptive data		14* (a) Give characteristics of study participants (eg demographic, clinical, social) and	12 (Lines 224 220)
		information on exposures and potential confounders	(Lines 224-229)
		(b) Indicate number of participants with missing data for each variable of interest	N/A
		(c) Summarise follow-up time (eg, average and total amount)	N/A
Outcome data		15* Report numbers of outcome events or summary measures over time	12-13
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their	12-13 (Lines 239-255)
		precision (eg, 95% confidence interval). Make clear which confounders were adjusted for	(Enics 237-233)
		and why they were included	
		(b) Report category boundaries when continuous variables were categorized	N/A
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a	N/A
		meaningful time period	
Other analyses	17	Report other analyses done-eg analyses of subgroups and interactions, and sensitivity	13 (Lines 247 255)
		analyses	(Lines 247-233)
Discussion			
Key results	18	Summarise key results with reference to study objectives	13-14 (Lines 257-266)
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision.	18 (Lines 367-373)

Discuss both direction and magnitude of any potential bias

Interpretation 20 Give a cautious overall interpretation of results considering objectives, limitations,		13-18	
		multiplicity of analyses, results from similar studies, and other relevant evidence	
Generalisability	21	Discuss the generalisability (external validity) of the study results	13-18
Other information	1		
Funding	22	Give the source of funding and the role of the funders for the present study and, if	19
			(Lines 287-393)
		applicable, for the original study on which the present article is based	

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at http://www.strobe-statement.org.